Abstract
The reinforcing effects of D1-like and D2-likeagonists, and their capacity to modify cocaine self-administration, were compared in rats with extensive cocaine self-administration experience. Cocaine (0.01–1.0 mg i.v.) dose-dependently maintained responding under a fixed ratio (FR) 5 schedule of reinforcement, and an inverted U-shaped function characterized the relationship between unit dose and self-administration behavior. When substituted for cocaine, the D1-like agonists SKF 82958 (0.001–0.032 mg i.v.) and SKF 77434 (0.001–0.1 mg i.v.) did not maintain responding above levels observed during saline substitution. In contrast, the D2-like agonists quinelorane (0.001–0.1 mg i.v.) and 7-hydroxy-dipropylaminotetralin (7-OH-DPAT; 0.01–0.32 mg i.v.) reliably maintained i.v. self-administration behavior that was characterized by inverted U-shaped dose-effect functions. Pretreatment with the D1-like agonists SKF 82958 and SKF 77434 (0.1–1.0 mg/kg i.p.) shifted the dose-effect function for cocaine self-administration downward, whereas pretreatment with the D2-like agonists quinelorane (0.01 mg/kg i.p.) and 7-OH-DPAT (0.32–1.0 mg/kg i.p.) shifted the cocaine dose-effect function to the left. Effects of D1-like and D2-like agonists on patterns of responding maintained by cocaine (0.32 mg i.v.) also differed: D1-like agonists increased the latency to the first response but did not otherwise alter patterns of cocaine self-administration, whereas D2-likeagonists increased the intervals between self-administered cocaine injections. The results suggest that D2-like agonists, but not D1-like agonists, have prominent reinforcing effects and enhance the effects of self-administered cocaine in rats with extensive cocaine self-administration experience. Consequently, D2 receptor-related neuronal mechanisms may be especially important in mediating the abuse-related effects of cocaine.
Footnotes
-
Send reprint requests to: S. Barak Caine, Alcohol and Drug Abuse Research Center, Harvard Medical School-McLean Hospital, 115 Mill Street, Belmont, MA 02478. E-mail:barak{at}mclean.harvard.edu
-
↵1 This research was supported in part by Grants T32-DA07252, P50-DA04059, and K05-DA00101 from the National Institute on Drug Abuse, National Institutes of Health. Preliminary data were presented to the College on Problems of Drug Dependence in 1998 and to the Society for Neuroscience in 1997.
- Abbreviations:
- 7-OH-DPAT
- 7-hydroxy-dipropylaminotetralin
- FR
- fixed ratio
- A50
- dose calculated to produce 50% of the measured effect
- TO
- timeout
- Received January 29, 1999.
- Accepted June 9, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|